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Introduction: Mesenchymal stem cells (MSCs)-based therapies have had positive outcomes in animal models of
cardiovascular diseases. However, the number and function of MSCs decline with age, reducing their ability to
contribute to endogenous injury repair. The potential of stem cells to restore damaged tissue in older individuals
can be improved by specific pretreatment aimed at delaying senescence and improving their regenerative
properties. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that modulates age-related
signaling pathways, and hence is a good candidate for rejuvenative function.
Methods: Bone marrow-derived mesenchymal stem cells (BM-MSCs) were isolated from young (6-month-old) or
aged (24-month-old) male donor rats. Cell proliferation was measured using the CCK8 cell proliferation assay;
secretion of VEGF, bFGF, HGF, and IGF was assessed by RT-qPCR and ELISA. Apoptosis was induced by hypoxia and
serum deprivation (hypoxia/SD) for up to 6 hr, and examined by flow cytometry. Expression levels of AMP-activated
protein kinase (AMPK) and forkhead box class O 3a (FOXO3a) were detected by Western blotting. CD74 expression
was assayed using RT-qPCR, Western blotting, and immunofluorescence.
Results: In this study, we found that MSCs isolated from the bone marrow of aged rats displayed reduced
proliferative capacity, impaired ability to mediate paracrine signaling, and lower resistance to hypoxia/serum
deprivation-induced apoptosis, when compared to younger MSCs. Interestingly, pretreatment of aged MSCs with
MIF enhanced their growth, paracrine function and survival. We detected enhanced secretion of VEGF, bFGF, HGF,
and IGF from MIF-treated MSCs using ELISA. Finally, we show that hypoxia/serum deprivation-induced apoptosis is
inhibited in aged MSCs following MIF exposure. Next, we found that the mechanism underlying the rejuvenating
function of MIF involves increased CD74-dependent phosphorylation of AMPK and FOXO3a. Furthermore, this effect
was abolished when CD74, AMPK, or FOXO3a expression was silenced using small-interfering RNAs(siRNA).
Conclusions: MIF can rejuvenate MSCs from a state of age-induced senescence by interacting with CD74 and
subsequently activating AMPK-FOXO3a signaling pathways. Pretreatment of MSCs with MIF may have important
therapeutic implications in restoration or rejuvenation of endogenous bone marrow-MSCs in aged individuals.* Correspondence: 244517813@qq.com
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Despite significant advances in the medical management
of heart failure, ischemia/reperfusion injury continues to
be a leading cause of death in developed countries [1].
In the last few years, many investigators have shown that
transplantation of bone marrow-derived mesenchymal
stem cells (MSCs) is a promising tool for the repair and
regeneration of cardiomyocytes as well as restoration of
heart function [2-4]. However, clinical studies together
with animal studies have shown that the regenerative
potential of bone and other tissues declines progressively
with age [5]. Consequently, transplantation of MSCs de-
rived from older donors appears to be less effective than
their younger counterparts [6]. If the age-dependent de-
crease in regenerative potential is caused by intrinsic
changes in MSCs themselves, autologous cell therapy
approaches are prone to be suboptimal in older patients,
who incidentally are in most need of such treatment
procedures [7]. Therefore, an optimum therapeutic strat-
egy for diseases associated with old age could be identifi-
cation of ways to replenish stem cell function by, for
instance, rejuvenating endogenous stem/progenitor cells
that might infiltrate and supply the ischemic tissue with
new blood vessels to prevent tissue damage [8-10].
Macrophage migration inhibitory factor (MIF) is a
pleiotropic cytokine that maintains homeostasis at set-
point levels by regulating physiological signaling path-
ways [11]. MIF is expressed in several cell types, includ-
ing monocytes and macrophages, vascular smooth
muscle cells and cardiomyocytes [12-14]. There is also
evidence that MIF exerts a fundamental role in the
metabolic response to environmental stress [11,15]. In
the heart, MIF is released by ischemic cardiomyocytes,
leading to enhanced glucose uptake and protection from
ischemic injury and cellular apoptosis. In addition, stud-
ies have shown that MIF expression is regulated by sen-
escence, and that in aged hearts its secretion is
significantly reduced. This in turn leads to dysregulation
of glucose uptake during both ischemia and reperfusion,
which is likely to account for reduced tolerance to ische-
mic stress in older individuals. However, researchers
have also shown that regaining MIF function attenuated
such an injury [16]. Furthermore, MIF also contributes
to cell survival and proliferation, and has been shown to
prevent cellular senescence [15,17]. In this study, we in-
vestigate whether MIF could rejuvenate aged MSCs and
enhance their function, so they could be applied to the
treatment of ischemic heart diseases.
Previous research has shown that MIF acts through the
AMP-activated protein kinase (AMPK) signaling pathway
to induce cellular resistance to glucose deprivation, is-
chemia, hypoxia, oxidative and senescent stress [15,18].
Activation of AMPK can slow down the process of sen-
escence [19], and has been investigated in mammals asa therapeutic target in age-related pathologies [20,21].
Interestingly, reduced AMPK activity in the aging heart
can be recovered when treated with MIF. In the present
study, we sought to examine whether AMPK activation
by MIF could restore the survival and function of aged
MSCs.
In addition to AMPK, we also explored the role of
Forkhead box class O 3a (FOXO3a) as a possible modu-
lator of MIF function during the rejuvenation of MSCs.
FOXO3a is a downstream effector of AMPK signaling,
and is known to be associated with human longevity
[22]. In addition, it has been implicated in the regulation
of diverse cellular functions including differentiation,
metabolism, proliferation and cell survival [23,24]. Down-
regulation of FOXO3a expression can accelerate cellular
senescence in human dermal fibroblasts and endothelial
cells [25].
Based on the above evidence, we hypothesized that
MIF activates AMPK–FOXO3a signaling to rejuvenate
MSCs from cellular senescence. This study was designed
to verify this hypothesis, and elucidate the influence of
MIF on aged MSCs.
Materials and methods
Animals
Young and mature (6 months old) and old (24 months
old) male Sprague–Dawley rats were maintained in ac-
cordance with guidelines published by the US National
Institutes of Health. All study procedures were approved
by the Harbin Medical University Institutional Animal
Care and Use Committee. This study was conducted in
compliance with the Guide for the Care and Use of
Laboratory Animals published by the National Academy
Press (National Institutes of Health, revised in 1996).
Reagents
Dulbecco’s modified Eagle’s medium and fetal bovine
serum were obtained from Hyclone (Logan, UT, USA).
Trizol reagent was obtained from Invitrogen (Carlsbad,
CA, USA). The First Stand cDNA Synthesis Kit, Fast
Start Universal SYBR Master (ROX) and X-treme GENE
HP DNA transfection reagent were obtained from Roche
(Mannheim, Germany). The Annexin V–fluorescein iso-
thiocyanate (FITC) Apoptosis Detection Kit and primary
antibodies anti-CD44, anti-CD29 and anti-CD90 were ob-
tained from BD Pharmingen (Franklin Lakes, NJ, USA).
The primary antibodies anti-CD34 and anti-CD45 were ob-
tained from eBioscience (San Diego, CA, USA). Rabbit
monoclonal antibodies against AMPKα, phospho-AMPKα
(Thr172), phospho-FoxO1(Thr24)/FoxO3a(Thr32) and
FoxO3a were purchased from Cell Signaling Technology
(Danvers, MA, USA). Rabbit monoclonal antibody anti-
CD74 was obtained from Santa Cruz Biotechnology (Dallas,
TX, USA). Mouse polyclonal antibody anti-β-actin was
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(#TA-09; Zhongshan Goldenbridge Biotechnology Co. Ltd,
Zhongshan, Guang Dong, China). Horseradish peroxidase-
conjugated anti-mouse and anti-rat secondary antibodies
were obtained from Santa Cruz Biotechnology. Alexa
Fluor 555-conjugated goat anti-rabbit IgG was procured
from Invitrogen. MIF, vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (bFGF), hepatocyte
growth factor (HGF) and insulin-like growth factor (IGF)
enzyme-linked immunosorbent assay kits were obtained
from Rapidbio (Winnetka, CA, USA). Small interfering
RNAs (siRNAs) targeted to AMPK and FOXO3a tran-
scripts were obtained from Life Technologies (Carlsbad,
CA, USA). siRNA targeted to CD74 was obtained from
QiaGen (Germantown, MD, USA). Rat recombinant MIF
was obtained from Prospec (East Brunswick, NJ, USA).
The cell proliferation assay, Cell Counting Kit-8 (CCK-8),
was obtained from HaiGene Technology (Harbin, China).
Cell culture and treatment
Bone marrow MSCs were isolated from the femur and
tibia of Sprague–Dawley rats as described previously
[26]. Briefly, bone marrow cells were flushed out from
the femur and tibia using 5 ml Dulbecco’s modified
Eagle’s medium/F12. Next, the red blood cells were lysed
and removed, and the remaining cells (5 × 105) were
plated on a 25 cm2 flask in 6 ml Dulbecco’s modified
Eagle’s medium/F12 supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. The cells were
cultures at 37°C and 5% carbon dioxide. After 3 days in
culture, the nonadherent cells were washed out, while
the adherent MSCs were grown further in the above
media, which was replaced every 3 days. Once the
culture reached 80 to 90% confluency, the cells were
trypsinized and passaged at 2:3 or 1:2 dilution. All cells
used in subsequent assays belonged to passages 3 to 5.
The characteristic properties of MSCs were demon-
strated by immunophenotyping. To verify the identity and
biological relevance of cultured MSCs, cells were labeled
using antibodies against various cell-surface markers
and analyzed by flow cytometry. Briefly, cultured MSCs
were harvested, washed with phosphate-buffered saline,
and immunostained with the following antibodies:
phycoerythrin-conjugated anti-CD45 and anti-CD90;
and FITC-conjugated anti-CD44, anti-CD29 and anti-
CD34. Labeled cells were assayed by flow cytometry,
and analyzed using the FACSDiva Pro Software (Becton-
Dickinson, San Jose, CA, USA).
For MIF stimulation, cells were fed with media contain-
ing 100 ng/ml recombinant MIF and incubated at 37°C
for various durations of time as described previously [27].
To induce apoptosis in vitro, culture conditions were
designed to mimic the hypoxia and serum deprivation
(hypoxia/SD) associated with ischemic myocardiumin vivo, in accordance with previous reports [28]. Briefly,
MSCs were incubated in serum-free media in a con-
trolled atmosphere (anaerobic chamber) glove box (Plas
Labs 855-AC; Lansing, PLAS LABS, INC., MI, USA) to
scavenge free oxygen. Cells exposed to hypoxia/SD alone
were used as apoptotic controls. In the experimental
condition, MIF (100 ng/ml) was added to the medium at
the time of exposure to hypoxia/SD and the cultures
were reincubated for 6 hours either in the absence or
continued presence of MIF under hypoxic conditions.
Cell proliferation assay
The rate of cell proliferation was estimated using the
CCK-8 assay, which was performed according to the
manufacturer’s protocol. Briefly, cells grown in a 96-well
plate were incubated with the CCK-8 solutions for 1 hour
at 37°C, following which the absorbance of each well at
450 nm was recorded.
Enzyme-linked immunosorbent assay
The concentration of secreted MIF, VEGF, bFGF, HGF
and IGF in the cell culture media was measured using
an enzyme-linked immunosorbent assay kit. Assays were
conducted in 96-well microplates according to the man-
ufacturer’s instructions.
Flow cytometric analysis of apoptosis
The extent of apoptotic cell death was assayed using the
Annexin V–FITC Apoptosis Detection Kit, performed
according to the manufacturer’s instructions, determined
by detecting phosphatidylserine exposure on cell plasma
membrane with the fluorescent dye. Briefly, cells were har-
vested and washed in ice-cold phosphate-buffered saline,
resuspended in 300 μl binding buffer and incubated with
5 μl Annexin V–FITC solution for 30 minutes at 4°C in the
dark. This was followed by incubation with 5 μl propidium
iodide for 5 minutes. The samples were immediately ana-
lyzed by bivariate flow cytometry on the BD FACSCantoII
equipped with Cell Quest software (BD Pharmingen, Bec-
ton-Dickinson, San Jose, CA). Approximately 1 × 105 to
5 × 105 cells were analyzed in each sample.
Knockdown of gene expression using small interfering RNA
MSCs were transfected using the X-treme GENE HP
DNA Transfection Reagent, according to the manufac-
turer’s instructions. Briefly, MSCs were cultured in a six-
well plate treated with the transfection reagent in a 3:1
ratio of reagent to siRNA weight for 20 minutes, followed
by addition of a mixture containing 100 nM siRNA, and
were incubated in 2 ml culture medium for 48 hours.
Scrambled small interfering RNA (siRNA-NT) was used
as the control. Transfection efficiency of siRNA-CD74,
siRNA-AMPK and siRNA-FOXO3a was determined by
western blotting.
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The expression levels of several genes were analyzed by
quantitative real-time PCR. Briefly, total cellular RNA was
isolated and reverse transcribed using the transcriptor First
Stand cDNA Synthesis Kit, according to the manufacturer’s
instructions. The quantitative PCR was carried out using
the Fast Start Universal SYBR Master and fluorescence
quantitative PCR system [23]. The threshold number of
cycles (Ct) was set within the exponential phase of the
PCR reaction, and the △Ct value for each target gene was
calculated by subtracting the Ct value of glyceraldehyde
3-phosphate dehydrogenase (internal control) from the
target gene. Relative gene expression levels were calculated
by comparing the △Ct values between control and experi-
mental conditions for each target PCR, and calculated
using the following equation:
Relative gene expression = 2–(△Ct sample – △Ct control).
The primer pairs used to detect the mRNA levels of
target genes are presented in Table 1.
Western blot
Western blot analyses were carried out as described previ-
ously [29]. Briefly, cells and tissue samples were washed
twice with ice-cold phosphate-buffered saline and rup-
tured with lysis buffer containing 20 mM Tris–HCl,
150 mM NaCl, 1% Triton X-100, and protease and phos-
phatase inhibitors. Tissue samples were further homoge-
nized using a rotorstator homogenizer. The lysates were
centrifuged for 5 minutes at 12,000 × g; the supernatant
consisted of total cellular protein. For each sample, 20 μg
total protein was resolved by SDS-PAGE and transferred
onto PVDF polyvinylidene difluoride membranes. Mem-
branes were blocked for 1 hour with 5% skim milk in Tris-














bFGF, basic fibroblast growth factor; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; HGF, hepatocyte growth factor; IGF, insulin-like growth factor;
MIF, macrophage migration inhibitory factor; VEGF, vascular endothelial
growth factor.overnight at 4°C with primary antibodies. The following
day, membranes were washed, incubated for 1 hour with
appropriate secondary antibodies conjugated to horserad-
ish peroxidase, and developed using chemiluminescent
substrates. The stained protein bands were visualized on
BIO-RAD ChemiDoc XRS equipment (Hercules, BIO-
RAD, CA, USA), and quantified and analyzed using the
Quantity One software (Hercules, BIO-RAD, CA, USA).
Immunofluorescent staining
To examine the expression of CD74 on the surface of
MSCs, cells were first grown on glass coverslips, fixed
with 4% paraformaldehyde for 15 minutes at room
temperature, blocked with 10% bovine serum albumin
and incubated with anti-CD74 primary antibody at 4°C
overnight. The following day, coverslips were washed,
and cells were incubated with Alexa Fluor 555-conjugated
goat anti-rabbit IgG for 1 hour at 37°C. Finally, the nuclei
were counterstained with 4,6-diamidino-2-phenylindole.
Images were acquired using a fluorescence microscope
(Leica DMI4000 B; Leica, Wetzlar, Germany).
Statistical analysis
Data are expressed as mean ± standard deviation. Statis-
tical significance of differences among groups was tested
by one-way analysis of variance. Comparisons between
two groups were performed using Student’s t test. P <0.05
was considered statistically significant.
Results
Downregulation of MIF expression in aged heart
First, we examined the expression levels of MIF in both
young and aged rat hearts. We found that both mRNA
and protein expression of cardiac MIF was markedly de-
creased in the older hearts (Figure 1), supporting our hy-
pothesis that the decrease in MIF expression and activity
is associated with ageing.
Expression and secretion of MIF is downregulated in aged
MSCs
First, we examined the basal level of expression of MIF
mRNA in aged and young MSCs using quantitative real-
time PCR. MIF transcript level in young cells was approxi-
mately eightfold higher than the older MSCs (Figure 2A).
Consistent with this, we also found a twofold to threefold
increase in the concentration of secreted MIF in the cul-
ture medium of young MSCs in comparison with the aged
cells (Figure 2B).
Exogenous MIF treatment restores the survival and
function of aged MSCs in a concentration-dependent
manner
Previous studies have shown that MIF promotes the sur-
vival and proliferation of neural stem/progenitor cells as
Figure 1 Downregulation of macrophage migration inhibitory factor
expression in aged heart. (A) Quantitative real-time PCR analysis of
macrophage migration inhibitory factor (MIF) mRNA levels in aged
and young heart tissue. (B), (C) Western blot analysis of MIF protein
levels in aged and young heart tissue. Each column represents the
mean ± standard deviation from three independent experiments;
*P <0.05 versus aged heart tissue.
Figure 2 Reduced expression and release of macrophage migration
inhibitory factor in aged mesenchymal stem cells. (A) Macrophage
migration inhibitory factor (MIF) mRNA levels analyzed by quantitative
real-time PCR in aged and young mesenchymal stem cells (MSCs).
(B) Concentration of MIF in the culture medium, analyzed by
enzyme-linked immunosorbent assay in cultures of aged and young
MSCs. Each column represents mean ± standard deviation from
three independent experiments; *P <0.05 versus aged.
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100 ng/ml [17,27]. To determine the optimal concentra-
tion for MIF function, we used a range of 1 to 1,000 ng/ml
to treat aged MSCs. Next, we assayed their proliferation
and found that a concentration of 100 ng/ml not only in-
duced the maximum rate of proliferation (Figure 3A) but
also induced the largest trophic effects, indicated by the
highest levels of secreted VEGF, bFGF, HGF and IGF
(Figure 3B,C,D,E).
To determine the effect of MIF exposure on the bio-
logical properties of aged MSCs, we first examined the
self-renewal potential of young and old MSCs using the
CCK-8 assay, and confirmed findings from previous re-
ports that demonstrated low rates of proliferation in
aged MSCs [30]. Interestingly, when we treated the aged
MSCs with MIF the proliferation rate increased signifi-
cantly starting from 1 day of treatment up to at least7 days, at which point the cultures started to resemble
young MSCs (Figure 4A).
MSCs secrete a variety of cytokines and growth factors
that can function in both a paracrine and an autocrine
manner. Such trophic effects of MSCs are known to be
impaired by senescence [31]. To determine whether MIF
can restore the trophic activity of MSCs isolated from
aged bone marrow, we performed quantitative real-time
PCR analysis of VEGF, bFGF, HGF and IGF expression.
As expected, in comparison with younger bone marrow
MSCs, the mRNA levels of all four factors was signifi-
cantly lower in aged cells, under both normal and hyp-
oxic conditions. Importantly, when we treated aged
MSCs with MIF, this difference was abolished in both
normal and hypoxic conditions (Figure 4B,C,D,E). Next,
we performed enzyme-linked immunosorbent assays to
quantify the levels of VEGF, bFGF, HGF and IGF in the
culture media of aged MSCs with and without MIF
treatment, and found an effect consistent with above re-
sults. MIF treatment significantly enhanced the secretion
Figure 3 Macrophage migration inhibitory factor induces rejuvenation in a concentration-dependent manner. (A) Proliferation growth curves of
mesenchymal stem cells incubated with macrophage migration inhibitory factor (MIF) at concentrations of 1 to 1,000 ng/ml, determined by the Cell
Counting Kit-8 (HaiGene Technology, Harbin, China) assay during 1, 3, 5 and 7 days of treatment. Each data point represents mean ± standard deviation
from three independent experiments; *P <0.05 versus 100 ng/ml MIF. Relative concentration of (B) vascular endothelial growth factor (VEGF), (C) basic
fibroblast growth factor (bFGF), (D) hepatocyte growth factor (HGF) and (E) insulin-like growth factor (IGF) analyzed by enzyme-linked immunosorbent
assay. Each column represents mean ± standard deviation from three independent experiments; *P <0.05 versus 100 ng/ml MIF.
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tions. Moreover, as seen before, the levels of secreted
trophic factors in MIF-exposed aged MSC cultures were
similar to the levels detected in cultures of young MSC
(Figure 4F,G,H,I).
Senescence reduces the regenerative potential of MSCs,
and is one of main reasons for increased susceptibility of
aged MSCs to apoptotic cell death under ischemicconditions [18]. Hence, we examined the effect of MIF on
the survival of aged MSCs, and found that these cells were
significantly less apoptotic than MSCs which were not ex-
posed to MIF. Interestingly however, MIF-treated aged
MSCs survived better than even young MSCs not treated
with MIF (Figure 4J,K). This suggests that MIF not only
has a restorative function on senescent MSCs, but might
also possess anti-apoptotic properties.
Figure 4 (See legend on next page.)
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Figure 4 Effect of macrophage migration inhibitory factor on proliferation, paracrine signaling and survival of mesenchymal stem cells. (A) Proliferation
growth curves of mesenchymal stem cells (MSCs), determined by the Cell Counting Kit-8 (HaiGene Technology, Harbin, China) assay, in young MSCs,
aged MSCs and aged MSCs treated with macrophage migration inhibitory factor (MIF; 100 ng/ml) during 1, 3, 5 and 7 days of treatment. Each data
point represents mean ± standard deviation from three independent experiments; *P <0.05 versus aged. mRNA levels of (B) vascular endothelial
growth factor (VEGF), (C) basic fibroblast growth factor (bFGF), (D) hepatocyte growth factor (HGF) and (E) insulin-like growth factor (IGF) analyzed by
quantitative real-time PCR in the culture of young, aged and MIF-treated aged MSCs, under normal and hypoxic conditions. Each column represents
mean ± standard deviation from three independent experiments; *P <0.05 versus aged. Relative concentration of (F) VEGF, (G) bFGF, (H) HGF and
(I) IGF analyzed by enzyme-linked immunosorbent assay, in the culture medium of young, aged and MIF-treated aged MSCs under normal and
hypoxic conditions. Each column represents mean ± standard deviation from three independent experiments; *P <0.05 versus aged. (J) Representative
distributions of propidium iodide (PI) and Annexin V staining from three FACScan flow cytometric analyses of apoptotic cells in normal and hypoxic
conditions, in cultures of young, aged and MIF-treated (100 ng/ml added at the point of exposure to hypoxia and serum deprivation (hypoxia/SD) and
maintained as such for 6 hours) MSC cultures: live (bottom left, Q-III), necrotic (top left, Q-I), early apoptotic (bottom right, Q-IV), late apoptotic
(top right, Q-II). (K) Fold-change of apoptotic cells compared with corresponding control cells. Each column represents mean ± standard deviation
from three independent experiments. *P <0.05 versus hypoxia/SD + aged, △P <0.05 versus normal + aged, ◇P <0.05 versus normal + young.
Figure 5 Effect of macrophage migration inhibitory factor on CD74 expression in mesenchymal stem cells. Expression of macrophage migration
inhibitory factor (MIF) (A)mRNA analyzed by quantitative real-time PCR and (B) protein analyzed by western blot. Each column represents mean ± standard
deviation from three independent experiments; P >0.05. (C) Densitometric quantification of MIF expression relative to internal control β-actin in young,
aged and MIF-treated aged mesenchymal stem cells (MSCs). (D) Immunofluorescent staining of CD74 in young, aged and MIF-treated aged MSCs.
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Figure 6 Macrophage migration inhibitory factor function is mediated through CD74. (A) Western blot analysis of CD74 expression in
untransfected mesenchymal stem cells (MSCs), and MSCs transfected with CD74-specific small interfering RNA (siRNA) and nontarget specific control
scrambled small interfering RNA (siRNA-NT). (B) Densitometric quantification of CD74 expression relative to internal control β-actin in all three conditions.
Each column represents mean ± standard deviation from three independent experiments; *P <0.05 versus siRNA-CD74. (C) Proliferation growth curves
(determined by the Cell Counting Kit-8 (HaiGene Technology, Harbin, China) assay) of untransfected and untreated MSCs, and macrophage migration
inhibitory factor (MIF)-treated control MSCs, CD74-siRNA transfected MSCs and siRNA-NT transfected MSCs. Each data point represents mean ± standard
deviation from three independent experiments; *P <0.05 versus MIF; △P <0.05 versus MIF + siRNA-NT. (D,E,F,G) Concentration of (D) vascular endothelial
growth factor (VEGF), (E) basic fibroblast growth factor (bFGF), (F) hepatocyte growth factor (HGF) and (G) insulin-like growth factor (IGF) under normal
and hypoxic conditions, in the culture medium of untransfected and untreated MSCs, and MIF-treated control MSCs, CD74-siRNA transfected MSCs and
siRNA-NT transfected MSCs. Each column represents mean ± standard deviation from three independent experiments; *P <0.05 versus MIF; △P <0.05
versus MIF + siRNA-NT.
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CD74-dependent signaling
CD74 is largely recognized as a receptor of MIF [27,32].
To elucidate the molecular mechanism underlying the
aforementioned restorative functions of MIF, we exam-
ined the effect of MIF treatment on the activity of
CD74-dependent signaling. First, we assayed the expres-
sion of CD74 quantitative real-time PCR, western blot
and immunofluorescence, and found no differences be-
tween aged MSCs, MIF-treated aged MSCs and young
MSCs (Figure 5A,B,C,D). To further analyze the role of
CD74, we knocked down its expression in aged MSCs
using siRNAs, and examined subsequent rates of prolifer-
ation, paracrine signaling and survival in aged MSCs, with
and without MIF treatment. As shown in Figure 6A,B,
siRNA transfection significantly decreased the mRNA and
protein levels of CD74, indicating efficient targeting of
gene expression by the specific siRNA used in this experi-
ment. More importantly, silencing of CD74 significantly
attenuated the rejuvenative effect of MIF, as seen by the
decrease in proliferation (Figure 6C), paracrine secretion
of VEGF, bFGF, HGF and IGF under both normal and
hypoxic conditions (Figure 6D,E,F,G), and an increase in
apoptotic cell death (Figure 7A,B). In contrast, we found
no differences in any of these parameters when aged
MSCs were transfected with control siRNA-NT.
Macrophage migration inhibitory factor exposure leads to
activation of the AMPK–FOXO3a signaling pathway
The AMPK–FOXO3a signaling pathway is an important
regulator of senescence in many cell types [33,34].
Therefore, we next investigated whether this mechanism
is involved in mediating the restorative effects of MIF in
MSCs. As shown in Figure 8A,B, western blot analysis
revealed low levels of detectable phospho-AMPK in con-
trol cells. In contrast, MIF exposure induced a pro-
nounced increase in the phosphorylation, and hence
activation, of AMPK, which was abolished by siRNA-
mediated silencing of CD74 expression. No differences
were observed in cells transfected with siRNA-NT. Simi-
larly, MIF exposure also caused a significant increase in
the phosphorylation of FOXO3a in MSCs. To determinewhether activation of FOXO3a is dependent on the activa-
tion AMPK, we silenced AMPK by transfecting specific
siRNAs, which significantly downregulated the expression
of AMPK. Silencing of AMPK expression abolished the
phosphorylation of FOXO3a subsequent to MIF treat-
ment, with no changes detected in the siRNA-NT trans-
fected cells (Figure 8E,F).
Rejuvenative function of MIF is mediated through CD74-
dependent AMPK–FOXO3a signaling
The data above suggest that AMPK–FOXO3a signaling
is likely to be involved in the mechanism of action of
MIF in aged MSCs. In order to elucidate this hypothesis,
we first silenced AMPK and FOXO3a expression using
siRNAs. As shown in Figure 8, siRNA-AMPK and siRNA-
FOXO3a significantly downregulated the expression of
AMPK and FOXO3a, respectively (Figure 8C,D,G,H).
Next, we analyzed the effect of the knockdown on
the proliferation, paracrine signaling and survival of
aged MSCs under a hypoxia/SD condition. As shown
in Figure 9A, knockdown of both AMPK and FOXO3a
decreased the extent of proliferation starting from 1 day
of treatment up to at least 7 days. Transfection with
siRNA-NT did not lead to any changes. The knockdown
also impaired the secretion of VEGF, bFGF, HGF
and IGF, under both normal and hypoxic conditions
(Figure 9B,C,D,E), and abolished the anti-apoptotic ef-
fects of MIF. The control siRNA-NT did not cause any
alterations in cell survival (Figure 9F,G).
Discussion
Autologous MSCs offer a great advantage when trans-
planted into ischemic or infarcted heart to regenerate
and repopulate the injured myocardium and restore
heart function. They are immunologically safe and easy
to prepare from adult patients [35]. However, like other
stem cells, MSCs are susceptible to age-related changes,
including increased rates of apoptosis and senescence,
and decreased rates of proliferation and paracrine sig-
naling [36-38], which reduce their ability to contribute
to endogenous injury repair processes [39]. Numerous
approaches have been attempted to overcome these
Figure 7 (See legend on next page.)
Xia et al. Stem Cell Research & Therapy  (2015) 6:82 Page 11 of 17
(See figure on previous page.)
Figure 7 Macrophage migration inhibitory factor restores cell survival through CD74. (A) Representative distributions of propidium iodide (PI)
and Annexin V staining from FACScan flow cytometric analyses of apoptotic cells in normal and hypoxia and serum deprivation (hypoxia/SD)
(6 hours) conditions, in cultures of untransfected and untreated mesenchymal stem cells (MSCs), and macrophage migration inhibitory factor
(MIF)-treated (100 ng/ml at the point of exposure to hypoxia/SD) control MSCs, CD74-small interfering RNA (siRNA) transfected MSCs and
scrambled small interfering RNA (siRNA-NT) transfected MSCs. MIF was added to the incubation medium throughout the hypoxia/SD treatment
period. (B) Fold-change of apoptotic cells in above conditions, compared with control. Each column represents mean ± standard deviation from
three independent experiments; *P <0.05 versus control; △P <0.05 versus hypoxia/SD; ◇P <0.05 versus hypoxia/SD + siRNA-CD74.
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ments in cardiac function, specifically in a rodent
model of acute myocardial infarction [30]. However,
despite these successes, researchers continue to ex-
plore ways to make the regenerative process easier to
achieve and more effective in restoring biological
function.
Results of the current study suggest that MIF treat-
ment can effectively rejuvenate MSCs isolated from age-
induced senescent rats. We further show that this func-
tion is mediated through activation of the CD74-
dependent AMPK–FOXO3a signaling pathway, leading
to increased proliferation and paracrine signaling activity
and decreased hypoxia/SD-induced apoptosis. Our data
strongly suggest that MIF is a promising candidate for a
rejuvenating agent for application in cell transplantation
therapy in age-induced senescent patients.
Aging is an important risk factor for cardiovascular
diseases. Furthermore, with the onset of such conditions,
which often occurs secondary to atherosclerotic plaque-
induced narrowing of blood vessels, the function of both
resident and circulating stem and progenitor cells is di-
minished [40,41]. The cumulative effect of these disease-
related and age-related deficits may contribute to a se-
vere decrease in the proliferation, paracrine signaling
and survival of stem cells [30]. Here, we show that aged
MSCs can regain their biological properties following ex-
posure to MIF, in most cases, to the extent that they
start to resemble young MSCs. Specifically, they display
increased proliferation rates, paracrine function and re-
sistance to apoptosis. Our data corroborate previous
findings that MIF exerts an anti-apoptotic effect in car-
diomyocytes exposed to an ischemic environment
[16,42]. Here, we show that aged MSCs, when treated
with MIF, show a lower degree of early apoptosis than
young untreated MSCs. Furthermore, researchers have
shown that circulating MIF levels are increased during
myocardial infarction but diminished during aging, sug-
gesting that MIF-mediated signaling and its protective
effects are active during cardiac ischemia but impaired
by senescence [43].
MIF is a proinflammatory cytokine, originally identi-
fied to play an important role in chronic inflammatory
diseases [44]. MIF also contributes to cell survival and
proliferation, and prevents cellular senescence [15,17].Mechanisms underlying MIF-dependent biological func-
tions are still being investigated, but have been shown to
involve activity of the AMPK, mitogen-activated protein
kinase/extracellular signal-regulated kinase and phos-
phoinositide 3-kinase/Akt signaling pathways. There is
large evidence that these mechanisms are important for
cellular proliferation, survival and senescence [11,18,45].
Endogenous MIF seems to exert a protective effect to
modulate the cellular energy state leading to increased
ATP production and limited energy consumption, espe-
cially in conditions such as glucose deprivation, ische-
mia, hypoxia, oxidative stress and senescence. With
regard to senescence, studies have shown that MIF ex-
pression is reduced in aged hearts [15]. Previous studies
have shown that cardiomyocytes in mice deficient in
MIF (MIF−/−) exhibit contractile defects in response to
starvation [46], and undergo increased apoptosis during
ischemia/reperfusion in vivo [47]. In addition, mice defi-
cient in either MIF (MIF−/−) or the MIF receptor CD74
(CD74−/−) activate the expression of markers of senes-
cence pathways p53/21 and p16, and develop spontaneous
emphysema by 6 months of age [48]. We corroborated
these findings in our study, and showed significantly de-
creased expression of MIF in aged heart tissue, in com-
parison with younger hearts. Interestingly, we also
found that despite the reduced basal level of expression,
aged MSCs can also secrete MIF. In contrast, younger
MSCs express MIF at higher levels. Moreover, MSCs
also express CD74, suggesting that the MIF released by
these cells might have autocrine function. Hence, strat-
egies that can facilitate regaining of endogenous MIF
level and activity might provide an additive effect while
using MSCs to treat ischemic heart diseases, especially
in aged patients.
CD74 is a well known receptor of MIF, shown to acti-
vate downstream signaling through a membrane recep-
tor complex [11,32,49]. MIF binds to CD74 through its
N-terminal region, which is also the site of its intrinsic
tautomerase activity, considered to be vestigial and non-
physiological [32]. Consistent with previous reports, we
found no difference in CD74 expression between aged
and young MSCs. Interestingly, although treatment with
MIF did not influence CD74 expression in MSCs,
siRNA-mediated knockdown of CD74 in the latter sig-
nificantly diminished the rejuvenating effect of MIF.
Figure 8 Macrophage migration inhibitory factor induces CD74-dependent activation of the AMPK-FOXO3a signaling pathway. (A, B) Representative
images of western blots of AMP-activated protein kinase (AMPK) and phospho-AMPK in mesenchymal stem cells (MSCs) transfected with CD74-small
interfering RNA (siRNA) or scrambled small interfering RNA (siRNA-NT) before pretreatment with macrophage migration inhibitory factor (MIF) (100 ng/ml)
and incubated in normal conditions for the indicated time. Fold-changes were calculated normalized to AMPK. Each column represents mean ± standard
deviation from three independent experiments; *P <0.05 versus control; △P <0.05 versus siRNA-CD74. (C, D) Representative images of western blots of
AMPK and β-actin in MSCs transfected with siRNA against AMPK genes, and siRNA-NT. Each column represents mean ± standard deviation from three
independent experiments; *P <0.05 versus siRNA-AMPK. Fold-changes were calculated normalized to β-actin. (E, F) Representative images of western
blots of Forkhead box class O 3a (FOXO3a) and phospho-FOXO3a in MSCs transfected with siRNA-AMPK or siRNA-NT before pretreatment with MIF
(100 ng/ml) and incubated under normal conditions for the indicated time. Fold-changes were calculated normalized to FOXO3a. Each column
represents mean ± standard deviation from three independent experiments; *P <0.05 versus control; △P <0.05 versus siRNA-AMPK. (G, H) Representative
images of western blots of FOXO3a and β-actin in MSCs transfected with siRNA against FOXO3a genes, and siRNA-NT. Fold-changes were calculated
normalized to β-actin. Each column represents mean ± standard deviation from three independent experiments; *P <0.05 versus siRNA-FOXO3a.
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MIF are mediated through CD74-dependent signaling,
consistent with studies that showed improved survivaland proliferation of neural stem/progenitor cells and B
cells in response to MIF exposure through activation of
a CD74-dependent pathway [17,27].
Figure 9 (See legend on next page.)
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Figure 9 Macrophage migration inhibitory factor restores cell rejuvenation through CD74-dependent AMPK–FOXO3a signaling. (A) Proliferation
growth curves of mesenchymal stem cells (MSCs) transfected with small interfering RNA (siRNA)-AMP-activated protein kinase (AMPK), siRNA-Forkhead
box class O 3a (FOXO3a), or scrambled small interfering RNA (siRNA-NT) control, and treated with macrophage migration inhibitory factor (MIF). Each
data point represents mean ± standard deviation from three independent experiments; *P <0.05 versus control; △P <0.05 versus MIF + siRNA-AMPK;
◇P <0.05 versus MIF + siRNA-FOXO3a. Concentration of (B) vascular endothelial growth factor (VEGF), (C) basic fibroblast growth factor (bFGF), (D)
hepatocyte growth factor (HGF) and (E) insulin-like growth factor (IGF) under normal and hypoxic conditions, in the culture medium of MSCs
transfected with siRNA-AMPK, siRNA-FOXO3a or siRNA-NT control, and treated with MIF. Each column represents mean ± standard deviation
from three independent experiments; *P <0.05 versus control; △P <0.05 versus MIF + siRNA-AMPK; ◇P <0.05 versus MIF + siRNA-FOXO3a. (F)
Representative distributions of propidium iodide (PI) and Annexin V staining from FACScan flow cytometric analyses of apoptotic cells in normal
and hypoxia and serum deprivation (hypoxia/SD) (6 hours) conditions, in cultures of MSCs transfected with siRNA-AMPK, siRNA-FOXO3a or
siRNA-NT control, and treated with MIF (100 ng/ml at the point of exposure to hypoxia/SD). MIF was added to the incubation medium throughout
the hypoxia/SD treatment period. (G) Fold-change of apoptotic cells in the above conditions, compared with control. Each column represents
mean ± standard deviation from three independent experiments; *P <0.05 versus control; △P <0.05 versus hypoxia/SD + MIF; ◇P <0.05
versus hypoxia/SD + siRNA-NT.
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key regulator of pathways that control energy generation
and consumption [50,51]. Cellular aging might be the
consequence of either the exhaustion of a metabolite
or a regulatory factor, or the unavoidable accumulation of
damage, including proteotoxicity, and oxidative, metabolic
and DNA damage [52-54]. In higher organisms, AMPK
plays a critical role in metabolism and stress-associated
cellular processes [55]. Studies have suggested that AMPK
signaling is involved in regulating efficient energy con-
sumption, by mediating metabolic homeostasis, enhanced
stress resistance and qualified cellular housekeeping,
which are the hallmarks of improved health and extended
lifespan [56]. There is emerging evidence that the respon-
siveness of AMPK signaling clearly declines with age [57].
This loss of sensitivity to cellular stress in turn impairs
metabolic regulation, increases oxidative stress and re-
duces autophagic clearance [56]. In the present study we
show that MIF exposure leads to phosphorylation and ac-
tivation of AMPK, consistent with other studies in which
several upstream kinases, including serine/threonine kin-
ase 11 (LKB1) [58], Ca2+/calmodulin-dependent protein
kinase kinase β (CaMKKβ) [59] and transforming growth
factor-beta-activated kinase 1 (TAK1) [60], were shown to
activate AMPK by phosphorylating the catalytic alpha
subunit at Thr172. This in turn enabled effective regulation
of energy metabolism and cellular homeostasis. We fur-
ther show that activation of AMPK is mediated through a
CD74-dependent pathway, since silencing of CD74 ex-
pression in MSCs led to impaired phosphorylation of
AMPK. In addition, siRNA-mediated silencing of AMPK
led to a significant decline in the restoration of cellular
function in aged MSCs in response to MIF. This suggests
that AMPK-mediated signaling is essential for the rejuven-
ating activity of MIF.
FOXO3a is a member of the mammalian FoxO family
of Forkhead transcription factors, and is involved in the
regulation of several important cellular functions, includ-
ing apoptosis, cell cycle, stress resistance, glucose and lipidmetabolism and inflammation [61,62]. FOXO3a is also a
key player in the regulation of longevity [22], and has been
closely associated with cellular senescence [63]. FOXO3a
can inhibit nuclear factor-κB signaling through the activa-
tion of inhibitory κB genes, IκBβ and IκBε, thus prevent-
ing age-related inflammatory responses [64]. Furthermore,
AMPK/FOXO3a signaling is known to inhibit the activity
of p38α kinase, an inducer of cellular senescence [65].
Studies have demonstrated in mouse fibroblasts that
AMPK can directly phosphorylate FOXO3a at six threo-
nine/serine residues within the transactivation domain.
They also showed that the AMPK–FOXO axis is involved
in regulating lifespan and its extension [66,67]. In the
current study, we show in MSCs that FOXO3a is phos-
phorylated at Thr32 in response to MIF exposure, and that
this could be abolished by silencing AMPK expression.
Furthermore, silencing of FOXO3a diminished MIF-
induced rejuvenation of aged MSCs, suggesting that the
restorative function of MIF in MSCs is mediated through
the AMPK–FOXO3a signaling pathway.
In the present study, we demonstrate that exogenous
supply of MIF can effectively rejuvenate the function of
senescent MSCs. Using both in vitro and in vivo assays
we show that senescence decreased the expression of
MIF, consistent with previous findings that MIF expres-
sion is impaired under certain stress conditions. From a
clinical perspective, the protective effect of exogenous
MIF during ischemic heart diseases may not only be due
to energy modulation, protection of cardiomyocytes and
regulation of cardioprotective proteins, but also due to
their rejuvenative effect on circulating stem cells. The
above findings suggest that pharmacological interventions
which restore MIF and related signaling pathways in the
senescent heart might be useful in reducing cardiac dam-
age caused by ischemic injury in older individuals.
Conclusions
Our study shows that pretreatment with MIF can reju-
venate MSCs derived from the bone marrow of aged
Xia et al. Stem Cell Research & Therapy  (2015) 6:82 Page 16 of 17donors. Specifically, MIF can positively influence the rate
of proliferation and paracrine signaling and alleviate
hypoxia/SD-induced apoptosis in senescent MSCs. The
demonstration that MSCs can be manipulated to cause
a delay in senescence and enhance their regenerative
properties has important therapeutic implications for
vascular disorders. Pretreatment of MSCs with MIF might
be extremely useful in cell transplantation-based repair
and regeneration of peripheral vasculature and its coron-
ary counterpart.
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